Compare KKR & Co Inc (KKR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Neurocrine Biosciences Inc — how do they compare? KKR & Co Inc trades at $111.1 (market cap $99.61B), while Neurocrine Biosciences Inc trades at $156.87 (market cap $16.46B). The key difference: KKR & Co Inc is far larger — about 6.1× Neurocrine Biosciences Inc's market cap, and KKR & Co Inc pays a 0.7% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| KKR | NBIX | |
|---|---|---|
Market Cap | $99.61B | $16.46B |
Sector | Financials | Health |
52-Week High | $149.34 | $185.50 |
52-Week Low | $83.88 | $123.10 |
Enterprise Value | $22.17B | $16.48B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR's stock trades at $110.37, up 6.3% today, showing strong momentum near recent highs. The technical outlook is bullish with the price above key moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.63, beating estimates of $1.43, with revenue growth supported by recent acquisitions including Integer Holdings and Medicover India. Analyst sentiment remains overwhelmingly positive with 24 buy ratings and a $127.22 consensus price target.
KKR presents a compelling investment case with strong earnings momentum, strategic acquisitions expanding its healthcare and infrastructure portfolios, and robust analyst support. However, risks include execution challenges from recent M&A activity, potential market volatility affecting asset valuations, and the stock's current premium valuation multiples. The company's ability to integrate acquisitions and maintain fundraising momentum will be key drivers of future performance.
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
